Gilead's Next HIV Triple-Combo Pill May Prevent Generic Erosion; Can It Prevent Infection Itself?
This article was originally published in The Pink Sheet Daily
Executive Summary
The company filed for FDA approval of a combination of Truvada with J&J's investigational non-nucleoside reverse transcriptase inhibitor TMC278, a regimen that could supplant Atripla.
You may also be interested in...
Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up
Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.
Tibotec Files Once-Daily NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
Studies supporting the application had a mysterious difference in outcomes. Further analysis of virologic failures is under way, says lead investigator.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.